Tag
This review synthesizes current evidence on the association between switching from combustible cigarettes to noncombustible nicotine/tobacco products and the risk of major vision-impairing eye diseases, highlighting a nationwide Korean coho
Young survivors of aneurysmal subarachnoid hemorrhage face a lifelong risk of developing new aneurysms, with female sex, smoking, and family history as key risk factors. Smoking cessation reduces this risk, supporting need for lifelong surv
The CASTL trial evaluated efficient combinations of tobacco cessation interventions for smokers undergoing lung cancer screening, identifying loss-framed messaging with nicotine replacement therapy as the most cost-effective strategy.
A cancer program quality improvement initiative reached a 100% smoking-status ask rate through an electronic hard stop, but assistance for identified smokers remained inconsistent, underscoring the implementation gap between screening and e
Recent clinical trials demonstrate that mobile chat-based interventions, combining live counselors and chatbots, significantly reduce smoking relapse rates and improve long-term abstinence through personalized, real-time support and engagem
An mHealth text messaging intervention significantly improves smoking cessation rates and reduces mortality among TB patients compared to usual care, supporting its implementation in TB programs.
This review examines the safety and effectiveness of electronic cigarettes as aids to quit smoking, showing increased abstinence rates compared to traditional therapies and no significant serious adverse events reported.
Updated Cochrane review finds nicotine e-cigarettes increase smoking cessation success compared to NRT and non-nicotine e-cigarettes, with no clear difference in serious adverse events.
A longitudinal, nationally representative cohort study found that within-person transition from current to former cigarette smoking was associated with a 30–43% higher odds of sustained recovery from other substance use disorders, supportin
New research reveals that quitting smoking in mid to late life significantly slows cognitive decline, offering an added three years of brain health regardless of quitting age.
Smoking cessation in middle-aged and older adults is linked to a slower decline in memory and fluency over six years, suggesting quitting smoking benefits long-term cognitive health regardless of age at cessation.
Nurse-led interventions, especially intensive counseling combined with varenicline or family-based approaches, significantly enhance smoking cessation rates. Brief advice and counseling also improve outcomes over usual care, supporting nurs
Cytisinicline significantly improves smoking cessation rates and is well tolerated in smokers with self-reported COPD, supporting its use as an effective treatment option for this high-risk population.
The Smart-T smartphone intervention significantly improves 7-day smoking abstinence at 26 weeks in low-income adults, outperforming the standard QuitGuide app when combined with nicotine replacement therapy.
This analysis reveals that varenicline is the most effective and safe pharmacotherapy for smoking cessation in individuals with current or past major depressive disorder, outperforming bupropion and nicotine patches with no increased neurop
The ORCA-3 trial confirms cytisinicline’s efficacy and safety for smoking cessation at 6 and 12 weeks, showing sustained abstinence and reduced nicotine craving up to 24 weeks.
This review synthesizes evidence from a randomized trial and real-world studies showing esketamine’s efficacy and safety in smoking cessation among lung cancer patients with MDD, as well as in treatment-resistant depression, highlight
Recent trials show no significant difference in smoking cessation rates between e-cigarettes and combination nicotine replacement therapy among patients discharged from inpatient substance use withdrawal services. Longitudinal analyses reve
